Genotype-Phenotype Correlations in Patients With Alport Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

8165 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-01-01

Study Completion Date

2030-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Alport syndrome (AS) is caused by pathogenic variants in the type IV collagen genes COL4A3, COL4A4, and COL4A5. This study aims to enroll families and patients with a history of renal hematuria in 27 hospitals and detect these three genes for AS screening. This study also aims to analysis the effect of COL4A3/COL4A4/COL4A5 genotype on the development of kidney disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Study and Gene Mutation Analysis of Adrenoleukodystrophy in Taiwanese Children

NCT00278044

Adrenoleukodystrophy

UNKNOWN NA

Angiotensin Converting Enzyme Gene Polymorphism in Children With Idiopathic Nephrotic Syndrome

NCT00172276

Nephrotic Syndrome

COMPLETED

Hematological Disorder in Patients With Angiodysplasia

NCT06050798

Angiodysplasia Hematological Disease

NOT_YET_RECRUITING

Sarcopenia and Osteoporosis in the Patients With Hemophilia

NCT04535180

Sarcopenia Hemophilia Osteoporosis, Osteopenia +1 more

COMPLETED

Some Hematological Profile in Children With Chronic Kidney Disease

NCT06143098

CKD Hematological Disease

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Alport syndrome (AS) is a genetically and phenotypically heterogeneous disorder caused by the mutations in the type IV collagen genes COL4A3, COL4A4, and COL4A5. In this study, next generation sequencing is used to screen AS on 8165 participants enrolled from families and patients with a history of renal hematuria in 27 hospitals of China Huadong Region. Genotype (variants in COL4A3/COL4A4/COL4A5)-phenotype (onset age of hearing loss, nephroticrange proteinuria, decline of eGFR, kidney survival and onset age of CKD5) correlations in AS were evaluated.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alport Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age: up to 99 Years (Child, Adult, Older Adult)
2. Sex: All;
3. Families and patients with a history of renal hematuria;
4. Those who signed the informed consent.

Exclusion Criteria

1. Polycystic kidney disease, hypertensive nephropathy, etc.;
2. Kidney biopsy is diagnosed as other primary/secondary kidney disease without type IV collagen-related kidney disease, including IgA nephropathy, membranous nephropathy, lupus nephritis, etc.
3. Incomplete medical history or clinical data.

Eligible Sex

ALL

Accepts Healthy Volunteers

No